Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
Abstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-85338-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832594790443646976 |
---|---|
author | Kunrong Yu Wanying Li Wenjie Long Yijia Li Yanting Li Huili Liao Jianhong Liu |
author_facet | Kunrong Yu Wanying Li Wenjie Long Yijia Li Yanting Li Huili Liao Jianhong Liu |
author_sort | Kunrong Yu |
collection | DOAJ |
description | Abstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating protein biomarkers for ILD and its subtypes. We utilized the most recent large-scale plasma protein quantitative trait loci (pQTL) data detected from the antibody-based method and ILD and its subtypes’ GWAS data from the updated FinnGen database for Mendelian randomization analysis. To enhance the reliability of causal associations, we conducted external validation and sensitivity analyses, including Bayesian colocalization and bidirectional Mendelian randomization analysis. Our study identified eight plasma proteins genetically associated with ILD or its subtypes. Among these, three proteins—CDH15 (Cadherin-15), LTBR (Lymphotoxin-beta receptor), and ADAM15 (A disintegrin and metalloproteinase 15)—emerged as priority biomarkers and potential therapeutic targets, demonstrating more reliable associations by passing a series of sensitivity analyses compared to the others. Based on these findings, we propose for the first time that CDH15, ADAM15, and LTBR hold promise as novel potential circulating protein biomarkers and therapeutic targets for the diagnosis and treatment of ILD, IPF, and sarcoidosis, respectively, especially ADAM15, and these findings have the potential to provide new perspectives for advancing the research on the heterogeneity of ILD. |
format | Article |
id | doaj-art-bfb00531060f419eb3c19c85453a32db |
institution | Kabale University |
issn | 2045-2322 |
language | English |
publishDate | 2025-01-01 |
publisher | Nature Portfolio |
record_format | Article |
series | Scientific Reports |
spelling | doaj-art-bfb00531060f419eb3c19c85453a32db2025-01-19T12:19:47ZengNature PortfolioScientific Reports2045-23222025-01-0115111310.1038/s41598-025-85338-yProteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung diseaseKunrong Yu0Wanying Li1Wenjie Long2Yijia Li3Yanting Li4Huili Liao5Jianhong Liu6Guangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineThe First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineThe First Affiliated Hospital of Guangzhou University of Chinese MedicineThe First Affiliated Hospital of Guangzhou University of Chinese MedicineAbstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating protein biomarkers for ILD and its subtypes. We utilized the most recent large-scale plasma protein quantitative trait loci (pQTL) data detected from the antibody-based method and ILD and its subtypes’ GWAS data from the updated FinnGen database for Mendelian randomization analysis. To enhance the reliability of causal associations, we conducted external validation and sensitivity analyses, including Bayesian colocalization and bidirectional Mendelian randomization analysis. Our study identified eight plasma proteins genetically associated with ILD or its subtypes. Among these, three proteins—CDH15 (Cadherin-15), LTBR (Lymphotoxin-beta receptor), and ADAM15 (A disintegrin and metalloproteinase 15)—emerged as priority biomarkers and potential therapeutic targets, demonstrating more reliable associations by passing a series of sensitivity analyses compared to the others. Based on these findings, we propose for the first time that CDH15, ADAM15, and LTBR hold promise as novel potential circulating protein biomarkers and therapeutic targets for the diagnosis and treatment of ILD, IPF, and sarcoidosis, respectively, especially ADAM15, and these findings have the potential to provide new perspectives for advancing the research on the heterogeneity of ILD.https://doi.org/10.1038/s41598-025-85338-yInterstitial lung diseaseSubtypeProteinMendelian randomizationBiomarkerDrug target |
spellingShingle | Kunrong Yu Wanying Li Wenjie Long Yijia Li Yanting Li Huili Liao Jianhong Liu Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease Scientific Reports Interstitial lung disease Subtype Protein Mendelian randomization Biomarker Drug target |
title | Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease |
title_full | Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease |
title_fullStr | Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease |
title_full_unstemmed | Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease |
title_short | Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease |
title_sort | proteome wide mendelian randomization identifies causal plasma proteins in interstitial lung disease |
topic | Interstitial lung disease Subtype Protein Mendelian randomization Biomarker Drug target |
url | https://doi.org/10.1038/s41598-025-85338-y |
work_keys_str_mv | AT kunrongyu proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease AT wanyingli proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease AT wenjielong proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease AT yijiali proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease AT yantingli proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease AT huililiao proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease AT jianhongliu proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease |